drugset

drugset / Trial / NCT02183116

A Study to Access the Efficacy and Safety of Meloxicam in Patients With Osteoarthritis of the Knee

NCT02183116 ↗

Phase 4 Completed 30 enrolled Boehringer Ingelheim

NaSingle-groupOpen-labelTreatment

Summary

To Access the Efficacy and Safety of Meloxicam 7.5mg once daily over a treatment period of 56 days

Timeline

Start: 1998-10
Primary completion: 1999-02
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Meloxicam	Small molecule	7.5 mg	—

Indications